American journal of preventive cardiology最新文献

{"title":"Effectiveness of behavior change techniques in eHealth-based cardiac rehabilitation in patients with coronary artery disease: A systematic review","authors":"Emma R. Douma ,&nbsp;Tom Roovers ,&nbsp;Mirela Habibović ,&nbsp;Gert-Jan de Bruijn ,&nbsp;Jos A. Bosch ,&nbsp;Boris Schmitz ,&nbsp;Willem J. Kop ,&nbsp;on behalf of the TIMELY consortium","doi":"10.1016/j.ajpc.2024.100892","DOIUrl":"10.1016/j.ajpc.2024.100892","url":null,"abstract":"<div><h3>Background</h3><div>Participation in cardiac rehabilitation (CR) reduces risk of cardiovascular mortality, improves functional capacity and enhances quality of life in patients with coronary artery disease (CAD). eHealth-based CR can increase participation rates, but research into effective components is necessary. The objective of this systematic review was to identify effective behavior change techniques (BCTs) used in eHealth-based CR interventions.</div></div><div><h3>Methods</h3><div>A search of four databases (CINAHL, PubMed, PsychINFO, and MEDLINE) was conducted until January 10, 2023. Randomized controlled trials investigating eHealth-based interventions for patients with CAD were included. Risk of bias was assessed using the Effective Public Healthcare Practice Project tool. BCTs were coded following the Behavior Change Taxonomy. A best-evidence synthesis was conducted to determine the effectiveness of BCTs, with ratings ranging from A (strong evidence indicating either a positive effect (+) or no effect (-)) to D (no data collected).</div></div><div><h3>Results</h3><div>A total of 88 studies (25,007 participants) met the eligibility criteria. The interventions in these studies used 31 different BCTs. The most common BCTs were <em>instructions on how to perform the behavior</em> (k = 86), <em>social support</em> (k = 69) and <em>information about health consequences</em> (k = 56). The evidence for <em>action planning</em> was rated as A+ for medication adherence and diet. Conversely, for systematically decreasing the number of prompts/cues sent during an intervention, the evidence was rated as A- for physical activity, medication adherence and smoking cessation. The evidence for <em>feedback on behavior</em> was rated as A+ for medication adherence and A- for smoking cessation.</div></div><div><h3>Conclusions</h3><div>Action planning is effective as a BCT in eHealth-based CR, whereas reducing prompts/cues is not. <em>Feedback on behavior</em> may, depending on the behavior targeted, exert both positive and no effect, suggesting that BCT-behavior matching is important to optimize effectiveness of eHealth-based CR.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"20 ","pages":"Article 100892"},"PeriodicalIF":4.3,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Endothelial Progenitor Cells in Patients with Established Cardiovascular Disease Treated with PCSK9 Monoclonal Antibodies","authors":"Chen Gurevitz ,&nbsp;Osnat Itzhaki Ben Zadok ,&nbsp;Dorit Leshem-Lev ,&nbsp;Lital Hodeda ,&nbsp;Aviad Rotholz ,&nbsp;Ran Kornowski ,&nbsp;Alon Eisen","doi":"10.1016/j.ajpc.2024.100896","DOIUrl":"10.1016/j.ajpc.2024.100896","url":null,"abstract":"<div><h3>Background</h3><div>The role of circulating endothelial progenitor cells (cEPCs) in vascular repair and their association to cardiovascular protection is well established.</div></div><div><h3>Objectives</h3><div>We examined the effect of proprotein convertase subtilisin kexin type 9 monoclonal antibodies (PCSK9 mAb) on cEPCs in adults with hypercholesterolemia and cardiovascular disease, aiming to establish a pleotropic class effect.</div></div><div><h3>Methods</h3><div>Non-interventional prospective study in patients with cardiovascular disease treated with either evolocumab or alirocumab. Patients were sampled for cEPCs at baseline, 1- and 3-months following initiation of PCSK9 mAb. cEPCs were assessed using flow cytometry by expression of CD34/CD133 and vascular endothelial growth factor receptor (VEGFR)-2, and functionally by formation of colony forming units (CFUs) and by Mitochondrial Tetrazolium (MTT) assay, indicative of cEPCs viability.</div></div><div><h3>Results</h3><div>51 patients (median age 67 (IQR 63,74) years;63 % male, median low-density lipoprotein-cholesterol (LDL-C) 125 (102,165) mg/dL) were initiated on PCSK9 mAb therapy (evolocumab <em>n</em> = 22, alirocumab <em>n</em> = 29) for secondary prevention. Following 3-month treatment with PCSK9 mAb, there was an increase in CD34⁽⁺⁾VEGFR-2⁽⁺⁾ and CD133⁽⁺⁾VEGFR-2⁽⁺⁾ levels (0.50 % [IQR 0.30,1.04] to 1.36 % [0.89, 1.73], <em>p</em> &lt; 0.001 and 0.57 % [0.25,0.88] to 1.18 % [0.74,1.66], <em>p</em> &lt; 0.001, respectively). Functionally, increase in EPCs-CFUs was evident (0.5 [0.0,1.0] to 2.0 [1.5,2.5], <em>p</em> &lt; 0.001) with concomitant increase in MTT (0.11 [0.09,0.15] to 0.17 [0.12,0.21], <em>p</em> &lt; 0.001). Stratifying by PCSK9 mAb, both agents were associated with an increase in cEPCs level and function.</div></div><div><h3>Conclusions</h3><div>In hypercholesterolemic patients with cardiovascular disease treated with PCSK9 mAb, there is an increase in cEPCs levels and function from baseline levels. These findings, which persist in both evolocumab and alirocumab, might suggest a novel pleiotropic class effect.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"20 ","pages":"Article 100896"},"PeriodicalIF":4.3,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latent class analysis of cardiac structure and function and association with premature cardiovascular disease: The Coronary Artery Risk Development in Young Adults (CARDIA) study","authors":"Michael C. Wang ,&nbsp;Toluwalase Awoyemi ,&nbsp;Norrina B. Allen ,&nbsp;Ravi Shah ,&nbsp;Matthew Nayor ,&nbsp;Yuan Luo ,&nbsp;Joao A.C. Lima ,&nbsp;Donald M. Lloyd-Jones ,&nbsp;Sadiya S. Khan","doi":"10.1016/j.ajpc.2024.100889","DOIUrl":"10.1016/j.ajpc.2024.100889","url":null,"abstract":"<div><h3>Objective</h3><div>To generate data-driven phenogroups of cardiac structure and function based on echocardiographic measures assessed in asymptomatic middle-aged adults free of CVD, and examine associations between these newly defined phenogroups and incident premature cardiovascular disease (CVD).</div></div><div><h3>Methods</h3><div>Data were analyzed from participants in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort study free of CVD who underwent an echocardiogram at the Year 25 (2010-2011) in-person examination. Continuous echocardiographic measures of left heart structure, left ventricular systolic function (including strain) and diastolic function, right ventricular systolic function, and hemodynamic measures were included in latent class analysis to generate novel phenogroups. Associations between data-driven phenogroups and risk of premature CVD (coronary artery disease, stroke, or heart failure) were estimated using Cox proportional hazards regression adjusted for traditional CVD risk factors.</div></div><div><h3>Results</h3><div>Among 3361 participants, mean (standard deviation) age was 50.1 (3.6) years, 57% were female, and 46% were non-Hispanic Black. Three overall phenogroups were identified and labeled as: (1) optimal cardiac mechanics (36.2%); (2) suboptimal systolic function (38.2%); and (3) suboptimal diastolic function (25.6%). Over a median 8.9 years of follow-up, 121 premature CVD events occurred. Risk of CVD was higher in the suboptimal diastolic function group (unadjusted hazard ratio [HR] 4.08 [95% CI: 2.48, 6.71] and adjusted HR 1.95 [1.12, 3.40]) compared with the optimal group. The suboptimal systolic function group had a higher unadjusted risk of CVD (1.86 [1.10, 3.15]), which was attenuated after adjustment for CVD risk factors (1.36 [0.79, 2.36]).</div></div><div><h3>Conclusions and relevance</h3><div>Unbiased, data-driven clustering of echocardiographic measures in middle-aged adults identified distinct patterns of cardiac remodeling that were associated with risk of premature CVD. Premature CVD risk was highest with the pattern of suboptimal diastolic function. This suggests potential utility of a composite echocardiography-based index for prioritizing prevention strategies earlier in the life course.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"20 ","pages":"Article 100889"},"PeriodicalIF":4.3,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Holistic approach to preventive cardiology: Where tradition meets innovation (Fellow's Voice)","authors":"Amanpreet Singh Wasir","doi":"10.1016/j.ajpc.2024.100891","DOIUrl":"10.1016/j.ajpc.2024.100891","url":null,"abstract":"","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"20 ","pages":"Article 100891"},"PeriodicalIF":4.3,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"300,000 quitters and counting; A systematic approach to tobacco cessation","authors":"Renee Fogelberg ,&nbsp;Kelly C. Young-Wolff ,&nbsp;Jaya Nadella ,&nbsp;Mehreen Khan ,&nbsp;Yi-Fen Irene Chen ,&nbsp;Jamal S. Rana","doi":"10.1016/j.ajpc.2024.100894","DOIUrl":"10.1016/j.ajpc.2024.100894","url":null,"abstract":"<div><h3>Objective</h3><div>To describe Kaiser Permanente Northern California's (KPNC) systematic implementation of universal tobacco screening, evidence-based interventions, and performance measures to achieve long-term smoking cessation success.</div></div><div><h3>Methods</h3><div>We outline seven key components of KPNC's tobacco screening and intervention program that contributed to a significant decline in smoking prevalence. We also report changes in the prevalence of current smokers within KPNC from 2014 to 2023 using linear regression analyses.</div></div><div><h3>Results</h3><div>Key factors driving the success of the tobacco cessation program included risk-based screening algorithms, alert prompts for at-risk patients, system-wide medical champions, performance tracking, virtual coaching, widespread messaging, and comprehensive medication management. Implementing this multifaceted approach across all facilities was associated with a significant reduction in smoking prevalence, from 8.6% in 2014 to 5.8% in 2023 (p &lt; 0.0001).</div></div><div><h3>Conclusion</h3><div>Our comprehensive, system-wide approach resulted in substantial public health gains and highlights the potential of similar preventive strategies as healthcare systems transition toward value-based care.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"20 ","pages":"Article 100894"},"PeriodicalIF":4.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142702833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of cardiovascular disease and cardiovascular health with disability status in a nationally representative sample of US adults","authors":"G.J. Jerome ,&nbsp;C.L. Lilly","doi":"10.1016/j.ajpc.2024.100893","DOIUrl":"10.1016/j.ajpc.2024.100893","url":null,"abstract":"<div><div>Background: A better understanding of cardiovascular disease (CVD), and cardiovascular health (CVH) among adults with disabilities is needed to address disability related health disparities. Methods: This study analyzed National Health and Nutrition Examination Survey (NHANES) questionnaires, medical examinations, and 24-hour dietary recall data from 2013–2018 for adults age 20–79 years with and without self-reported disability. CVD was dichotomous based on self-report and CVH was assessed using American Heart Association Life's Essential 8 (LE8) comprised of four health behaviors (diet, physical activity, nicotine exposure, and sleep health) and four health factors (body mass index, blood lipids, blood glucose, and blood pressure) with higher scores indicating better CVH. Analyses incorporated the complex multistage NHANES sampling design. Results: The study included 1,300 adults with self-reported CVD and 13,656 adults who were CVD free. Separate weighted logistic regressions for age groups of 20–39, 40–59, and 60–79 years indicated adults with a disability had higher odds of CVD compared to those who were disability free (OR_adj (95 %CI) 8.0(4.6–14.1), 5.8(4.3–8.0), 2.5(1.9–3.3) respectively). Among those who were CVD free, CVH was lower for those with a disability compared to those without a disability for the total LE8 score (mean_adj(SE) 56.9(0.5) vs. 65.7(0.3), <em>p &lt;</em> .001) and all eight LE8 metrics (<em>p ≤</em> 0.004). Conclusion: These results are aligned with the call to action to improve health and wellness of persons with disabilities which should include wellness programming for health behaviors such as diet, physical activity, sleep health, and nicotine cessation.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"20 ","pages":"Article 100893"},"PeriodicalIF":4.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guideline recommended statin eligibility and use among U.S. adults ages 20 to 39 years","authors":"Shoa L. Clarke ,&nbsp;Blake Thomson","doi":"10.1016/j.ajpc.2024.100890","DOIUrl":"10.1016/j.ajpc.2024.100890","url":null,"abstract":"<div><h3>Objective</h3><div>Guidelines for statin therapy emphasize treatment of adults ages 40–75 years, with less guidance for the treatment of younger adults, ages 20–39 years. Only two class 1 recommendations for statin apply to younger adults: 1) secondary prevention and 2) severe hypercholesterolemia (LDL-C ≥ 190 mg/dL). The implementation of guidelines within this age group has not been well studied.</div></div><div><h3>Methods &amp; Results</h3><div>Here, we use data from the National Health and Nutrition Examination Survey (2013–2020) to estimate statin eligibility and use among US younger adults. Based on this nationally representative sample, we extrapolate that approximately 923,000 younger adults had a history of atherosclerotic cardiovascular disease, but only ∼24 % were on statin. Among younger adults in the primary prevention group, we extrapolate that at least 1.09 million had severe hypercholesterolemia. To expand on this analysis, we calculated untreated LDL-C values for individuals on statin using two methods, and we estimate that only ∼11–20 % of younger adults with severe hypercholesterolemia were on statin. Lastly, among untreated younger adults with a class 1 indication for statin, fewer than 25 % reported that a doctor or healthcare provider had recommended cholesterol medication.</div></div><div><h3>Conclusion</h3><div>The implementation of class 1 recommendations for statin treatment in younger adults is poor. While efforts to improve risk prediction in the young have recently received significant attention, our results indicate that identifying high risk younger adults is insufficient. We must also improve guideline-recommended treatment in this age group.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"20 ","pages":"Article 100890"},"PeriodicalIF":4.3,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142662457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoprotein(a) throughout life in women","authors":"Pablo Corral ,&nbsp;María Gabriela Matta ,&nbsp;Carlos Aguilar-Salinas ,&nbsp;Roopa Mehta ,&nbsp;Gabriela Berg ,&nbsp;Massimiliano Ruscica ,&nbsp;Laura Schreier","doi":"10.1016/j.ajpc.2024.100885","DOIUrl":"10.1016/j.ajpc.2024.100885","url":null,"abstract":"<div><div>Lipoprotein (a) [Lp(a)] is a lipoprotein with multiple deleterious characteristics and is a recognized cardiovascular (CV) risk factor. The pro-atherogenic, pro-thrombotic, and pro-inflammatory features of Lp(a) are associated not only with atherosclerotic vascular disease but also with aortic valve calcification and all-cause mortality. One of the most interesting aspects of Lp(a) is that its level is determined by genetics in more than 90% of cases, with lifestyle habits having very little influence. Therefore, the recommendation is to test it, at least, once in a lifetime. Contrary to previous beliefs, evidence in recent decades has shown that women have the same or even greater CV risk than men of the same age, attributed to female sex hormones. Different stages of a woman's life can impact on Lp(a) levels, from newborn to menopause, including other critical moments such as menarche and pregnancy. The main objective of this review is to describe and analyze the effect of different specific periods of a woman's life on Lp(a) levels and the potential clinical relevance on their CV risk.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"20 ","pages":"Article 100885"},"PeriodicalIF":4.3,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142662456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer","authors":"Elizabeth A. Kobe ,&nbsp;Aarti Thakkar ,&nbsp;Sarina Matai ,&nbsp;Esra Akkaya ,&nbsp;Neha J. Pagidipati ,&nbsp;Robert W. McGarrah ,&nbsp;Gerald S. Bloomfield ,&nbsp;Nishant P. Shah","doi":"10.1016/j.ajpc.2024.100888","DOIUrl":"10.1016/j.ajpc.2024.100888","url":null,"abstract":"<div><div>Effective antiretroviral therapy (ART) is now nearly ubiquitous. However, the survival benefits conferred with ART contribute to an aging human immunodeficiency virus (HIV) population and increased risk of chronic diseases, like atherosclerotic cardiovascular disease (ASCVD). Furthermore, HIV is a known risk enhancer of ASCVD and acknowledged as such in the current 2018 AHA/ACC Blood Cholesterol guidelines [1]. This makes cardiovascular risk factor identification and modification among people living with HIV (PLWH) of increasing importance to prevent cardiovascular events. In this review, we aim to summarize the epidemiology and pathogenesis of how HIV is linked to atherogenesis and to discuss cardiometabolic risk factor modification specific to PLWH, covering obesity, hypertension, insulin resistance, metabolic dysfunction-associated steatotic liver disease, and dyslipidemia.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"20 ","pages":"Article 100888"},"PeriodicalIF":4.3,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142571495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiodiabesity: Epidemiology, resource and economic impact","authors":"Duy Do,&nbsp;Tiffany Lee,&nbsp;Calie Santana,&nbsp;Angela Inneh,&nbsp;Urvashi Patel","doi":"10.1016/j.ajpc.2024.100887","DOIUrl":"10.1016/j.ajpc.2024.100887","url":null,"abstract":"<div><h3>Objective</h3><div>To assess i) the epidemiology of cardiodiabesity, ii) its association with healthcare resource utilization and cost of care, as well as iii) provide recommendations for its management.</div></div><div><h3>Methods</h3><div>A cohort study of insured adults with early-stage and/or active cardiodiabesity from January 2019 to December 2021 identified through a longitudinal, and de-identified medical and pharmacy claims database was conducted. All patients were followed for one year through December 2022. Conditions include cardiovascular disease, prediabetes, Type 2 diabetes (T2D), chronic kidney disease (CKD), overweight and/or obesity. Rates of progression from early-stage cardiodiabesity to active cardiodiabesity and/or advanced cardiodiabesity with complications; frequency of emergency department, inpatient and outpatient visits; as well as total cost of care over one year were analyzed.</div></div><div><h3>Results</h3><div>A total of 3,273,813 and 1,628,407 patients had at least one of the comorbid conditions for early-stage and active cardiodiabesity, respectively. Among those with all early-stage cardiodiabesity conditions, 27.4 % progressed to active cardiodiabesity, while 88.4 % of those with all active cardiodiabesity conditions progressed to complications within one year. Predictors of progression from early-stage to active cardiodiabesity were hypertension (OR: 2.31, 95 % CI: 2.29–2.33, <em>p</em> &lt; 0.001), hyperlipidemia (OR: 1.77, 95 % CI: 1.76–1.79, <em>p</em> &lt; 0.001), CKD stages 1 and 2 (OR: 1.74, 95 % CI: 1.69–1.79, <em>p</em> &lt; 0.001), prediabetes (OR: 1.64, 95 % CI: 1.63–1.66, <em>p</em> &lt; 0.001) and living in areas with very high social needs (OR: 1.25, 95 % CI: 1.23–1.26, <em>p</em> &lt; 0.001). Significant predictors of progression from active cardiodiabesity to complications were T2D (OR: 1.88, 95 % CI: 1.81–1.96, <em>p</em> &lt; 0.001), CVD (OR: 1.47, 95 % CI: 1.44–1.51, <em>p</em> &lt; 0.001), CKD stages 3 and 4 (OR: 1.37, 95 % CI: 1.34–1.41, <em>p</em> &lt; 0.001) and obesity (OR: 1.29, 95 % CI: 1.26–1.32, <em>p</em> &lt; 0.001). Average total cost of care increased significantly among those who progressed from one disease phase to the next (p &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>Cardiodiabesity is deadly and rapidly progressive with substantial economic burden on the healthcare system. However, it is preventable. Innovative approaches to better understand the holistic impact of cardiodiabesity on total cost of care, early intervention or management to halt disease progression and promote equity, as well as decrease resource utilization are needed.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"20 ","pages":"Article 100887"},"PeriodicalIF":4.3,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142662458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}